Alcon v. Padagis: Delaware Court Rules for Generic Challenger on All Infringement Claims
Alcon, Inc. and its affiliates sued Padagis over ANDA No. 212137, asserting two patents covering aqueous ophthalmic borate-polyol complex formulations. After a three-day bench trial in October 2024, Judge Bryson entered judgment for Padagis on every infringement count — while simultaneously finding Alcon’s claims 13-19 of US9,421,265 valid. The case ran 838 days from filing to final judgment.
Hatch-Waxman Battle Over Ophthalmic Borate-Polyol Formulations Ends in Generic Win
In October 2022, Alcon, Inc., Alcon Laboratories, Inc., and Alcon Vision, LLC filed this Hatch-Waxman patent infringement action in the District of Delaware against Padagis Israel Pharmaceuticals, Ltd., Padagis LLC, and Padagis US, LLC. The plaintiffs alleged that Padagis’s ANDA No. 212137 — seeking FDA approval for a generic aqueous ophthalmic product — infringed U.S. Patent Nos. 9,044,484 and 9,421,265, both directed to aqueous pharmaceutical compositions containing borate-polyol complexes used in ophthalmic formulations.
The case was resolved at the district court level following a three-day bench trial before Judge William C. Bryson from October 21 to 23, 2024. On February 5, 2025, the court issued its Findings of Fact and Conclusions of Law, and on February 11, 2025, entered final judgment. Padagis prevailed on all infringement claims across both patents — including literal infringement and doctrine of equivalents. Notably, the court upheld the validity of claims 13-19 of the ‘265 patent, meaning those claims survived but Padagis was found not to infringe them under the doctrine of equivalents. Invalidity counterclaims on several claim groups were dismissed without prejudice by stipulation.
At 838 days, the case reflects the typical complexity of Hatch-Waxman pharmaceutical litigation involving formulation chemistry patents and equivalents disputes. The split outcome — Padagis wins on infringement while Alcon’s patent claims survive validity challenge — is commercially significant: Padagis may now proceed toward FDA approval, but the valid patent may constrain future ANDA filers. Attorneys’ fees and exceptional-case motions remain available to both parties, suggesting further procedural activity is possible. The public record does not disclose settlement discussions or licensing terms.
Filing to Judgment on the merits for Defendant in 838 days
838 days from filing to final judgment — longer than the median Hatch-Waxman ANDA trial in Delaware
Defendant judgment: what Padagis’s win means for both parties
Judgment on the merits: no infringement across two patents
A judgment on the merits for the defendant in an ANDA case means the court found, after full trial, that the generic product did not infringe the asserted patent claims — either literally or under the doctrine of equivalents. This is not a dismissal; it is a substantive finding that clears the way for FDA to approve the ANDA without patent-based delay. The court applied the doctrine of equivalents analysis to claims 13-19 of the ‘265 patent and still ruled for Padagis.
Full merits adjudicationAlcon retains valid patents but loses enforcement against this ANDA
Alcon’s claims 13-19 of US9,421,265 were found valid by the court — a meaningful defensive win that preserves the patent for future enforcement. However, Alcon failed to establish infringement on any claim of either patent, meaning Padagis’s ANDA product was found to fall outside the patent scope. Alcon retains options to appeal the infringement findings or to pursue exceptional-case fee motions, but cannot block this ANDA solely on the basis of these patents as currently adjudicated.
Patents valid; infringement not provenPadagis cleared to pursue FDA approval on both patents
With judgment in its favour on all infringement claims, Padagis has cleared the primary patent barrier to FDA approval of ANDA No. 212137. The court’s ruling on the doctrine of equivalents — finding no infringement of claims 13-19 of the ‘265 patent — was particularly significant, as equivalents arguments are typically Alcon’s last line of defence after literal infringement fails. Invalidity counterclaims on several claim groups were dismissed without prejudice, preserving Padagis’s ability to raise them in future proceedings if needed.
ANDA pathway clearedGeneric ophthalmic market entry: what the ruling means for the sector
This outcome suggests borate-polyol ophthalmic formulation patents face meaningful non-infringement arguments at the equivalents stage. For other ANDA filers targeting similar ophthalmic formulations, the court’s reasoning on doctrine of equivalents scope — applied to a valid patent — provides a potentially useful litigation roadmap. Brand manufacturers holding composition patents in this space should evaluate whether claim drafting adequately captures equivalents, particularly for aqueous formulation chemistry where minor compositional differences may defeat equivalence arguments.
Ophthalmic generics market riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alcon, Inc. | Company | Global ophthalmic pharmaceutical company — holder of US9044484B2 and US9421265B2Search in Eureka ↗ |
| Co-Plaintiff | Alcon Laboratories, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Alcon Vision, LLC | Company | Search in Eureka ↗ |
| Defendant | Padagis Israel Pharmaceuticals, Ltd. | Company | Generic pharmaceutical manufacturer; filed ANDA No. 212137 for ophthalmic borate-polyol formulationSearch in Eureka ↗ |
| Co-Defendant | Padagis, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Padagis US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Russell | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ayyan S. Zubair | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Daniel P. Margolis | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Elizabeth J. Holland | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Emily DiBenedetto | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | John W. Shaw | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Karen Elizabeth Keller | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Katherine Kieckhafer | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mena Gaballah | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael Bruns | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michelle Bone | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Nathan Roger Hoeschen | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ryan C. Curiel | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William G. James | Attorney | Counsel for Alcon, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Shaw Keller LLP | Law Firm | Representing Alcon, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrea L. Cheek | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Andrew E. Morrell | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Aryeh N. Feinstein | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Carol M. Pitzel Cruz | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jared C. Bunker | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jeremiah S. Helm | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Jonathan E. Bachand | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Megan C. Haney | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Nyja A. Prior | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | Purna Chandrasekhar | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant counsel | William R. Zimmerman | Attorney | Counsel for Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Padagis Israel Pharmaceuticals, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge William C. Bryson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment reflects a nuanced split: Padagis prevails on every infringement theory across both patents, yet Alcon’s patent claims survive validity challenge. The court’s findings distinguish literal infringement from doctrine of equivalents analysis, applying each separately to specific claim groups. The dismissal without prejudice of certain invalidity counterclaims — entered by stipulation before trial — narrows the issues resolved on the merits. The preserved attorneys’ fees window under 35 U.S.C. § 285 signals the court anticipated continued procedural activity. Notably, the judgment was rendered after a three-day bench trial, giving the Findings of Fact and Conclusions of Law significant evidentiary weight on any appeal.
US9044484B2 & US9421265B2 — Aqueous Ophthalmic Borate-Polyol Formulations
US9,044,484 and US9,421,265 both protect aqueous pharmaceutical compositions that incorporate borate-polyol complexes — a formulation technology used in ophthalmic (eye-drop) products to improve stability, viscosity, and preservative compatibility. The ‘484 patent derives from application US12/817561 and the ‘265 from US14/690617, the latter being a continuation-type filing. This prosecution trajectory suggests Alcon built a layered patent family around this formulation chemistry, with claims of varying scope across the two patents.
Borate-polyol complexation technology is commercially relevant to a wide range of branded ophthalmic products, including lubricating eye drops and multi-dose preserved solutions. For generic manufacturers targeting this market segment, these patents represent a key barrier — which is precisely why Padagis filed Paragraph IV certifications triggering this litigation. The court’s finding that Padagis’s ANDA formulation did not infringe under the doctrine of equivalents, despite the patent’s validity, suggests the claims may not capture all commercially viable borate-polyol formulation variants. Other companies in the ophthalmic formulations space should assess their own product compositions against these patents.
Should you run an FTO against US9044484B2 and US9421265B2?
Any company developing or commercialising aqueous ophthalmic products — particularly those using borate or polyol-based formulation chemistry — should evaluate freedom to operate against these two Alcon patents. The ‘265 patent’s claims 13-19 have been affirmatively found valid by a Delaware district court, meaning they remain active enforcement tools. Even though Padagis’s specific ANDA formulation was found non-infringing, the legal standard applied was product-specific — a different formulation composition could reach a different infringement conclusion.
PatSnap Eureka’s FTO Search Agent can map your ophthalmic formulation against the asserted claim language of US9,044,484 and US9,421,265 in minutes, surfacing both literal and functional overlap risks. The tool also identifies related continuation patents and pending applications in Alcon’s prosecution family — critical for anticipating future enforcement. For ANDA filers and branded ophthalmic developers alike, an up-to-date FTO analysis against this patent family is commercially prudent given the confirmed validity of key claims.
Run a freedom-to-operate analysis on US9044484B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Ophthalmic Formulation Cases in Delaware District Court
Cases involving ANDA challenges to ophthalmic pharmaceutical formulation patents litigated in the District of Delaware before and after Alcon v. Padagis.
What Alcon v. Padagis signals for ophthalmic pharmaceutical IP strategy
A defendant win after full bench trial on borate-polyol formulation patents has concrete implications for both brand and generic ophthalmic companies.
Valid patents can still fail on infringement — equivalents are not guaranteed
The court upheld the validity of claims 13-19 of the ‘265 patent but still found no infringement under the doctrine of equivalents. This split outcome reinforces that patent validity alone does not block generic entry. Brand companies should stress-test equivalents coverage during prosecution, not just claim validity.
Stipulated dismissals of counterclaims without prejudice preserve future leverage
Multiple invalidity counterclaims were dismissed without prejudice by stipulation. This approach — common in ANDA litigation — means Padagis retains the ability to challenge validity in future proceedings. IP teams monitoring this space should track whether invalidity arguments resurface in IPR or follow-on litigation.
Alcon v Padagis — key questions answered
The Delaware District Court entered judgment for Padagis on all infringement claims across both asserted patents (US9,044,484 and US9,421,265) on February 11, 2025. Notably, the court found claims 13-19 of the ‘265 patent valid but not infringed under the doctrine of equivalents. The case was decided after a three-day bench trial in October 2024.
Alcon asserted U.S. Patent Nos. 9,044,484 (application US12/817561) and 9,421,265 (application US14/690617), both covering aqueous pharmaceutical compositions containing borate-polyol complexes used in ophthalmic formulations. Multiple claim groups were litigated, including claims 1-3, 6-23 of the ‘484 patent and claims 1-3, 6-19 of the ‘265 patent.
Yes. The court found claims 13-19 of US9,421,265 valid, rejecting Padagis’s invalidity counterclaims on those claims. However, validity alone did not prevent Padagis from winning the case — the court separately found those same claims were not infringed under the doctrine of equivalents, resulting in overall judgment for the defendant.
Certain invalidity counterclaims — covering claims 1-3 and 6-12 of the ‘265 patent and claims 1-3 and 6-23 of the ‘484 patent — were dismissed without prejudice by party stipulation. This means Padagis did not obtain a merits ruling on invalidity of those claim groups, but retains the ability to challenge their validity in future proceedings such as IPR or subsequent litigation if Alcon attempts to assert them again.
Yes. The court’s final judgment expressly preserved the right to file motions for attorneys’ fees under Fed. R. Civ. P. 54 and exceptional-case motions under 35 U.S.C. § 285. If no party appeals, such motions must be filed within 30 days after the appeal deadline expires. If an appeal is filed, the 30-day window runs from final disposition of that appeal. Either party could potentially file such a motion.
PatSnap Eureka searches patents and litigation data to answer instantly.